Yang Zhao

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Diabetes Complications 24:9-19. 2010
  2. ncbi A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients
    Luke Boulanger
    Health Economic Research and Quality of Life Evaluation, Abt Bio Pharma Solutions, Inc, Lexington, MA, USA
    BMC Health Serv Res 9:111. 2009
  3. ncbi Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    Curr Med Res Opin 27:785-92. 2011
  4. ncbi Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    Pain Pract 11:204-16. 2011
  5. ncbi Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies
    Y Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 26:2147-56. 2010
  6. ncbi Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    Pain Pract 11:381-91. 2011
  7. ncbi Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 25:585-97. 2009
  8. ncbi Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities
    Y Zhao
    Global Health Outcomes, Eli Lilly and Co, Indianapolis, IN 46221, USA
    Diabet Med 26:61-9. 2009
  9. ncbi Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Health Serv Res 8:108. 2008
  10. ncbi Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia
    Peter Sun
    Kailo Research Group, Indianapolis, IN 46038, USA
    Curr Med Res Opin 27:1793-801. 2011

Detail Information

Publications22

  1. ncbi Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Diabetes Complications 24:9-19. 2010
    ..Diabetic neuropathy (DN) is a common complication associated with diabetes. This study assesses the prevalence of other diabetes-related complications or comorbidities among DN patients and its marginal contribution to health care charges...
  2. ncbi A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients
    Luke Boulanger
    Health Economic Research and Quality of Life Evaluation, Abt Bio Pharma Solutions, Inc, Lexington, MA, USA
    BMC Health Serv Res 9:111. 2009
    ..No study has examined the differences in economic outcomes depending on the presence of comorbid DA disorders...
  3. ncbi Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    Curr Med Res Opin 27:785-92. 2011
    ..To examine the impact of medication choice between duloxetine or pregabalin on medication adherence and direct healthcare costs among patients with diabetic peripheral neuropathic pain (DPNP)...
  4. ncbi Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    Pain Pract 11:204-16. 2011
    ..To examine and compare medication adherence and direct healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia...
  5. ncbi Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies
    Y Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 26:2147-56. 2010
    ....
  6. ncbi Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine
    Yang Zhao
    Global Health Outcomes, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
    Pain Pract 11:381-91. 2011
    ..The study aims to examine predictors associated with duloxetine adherence and its association with healthcare costs among fibromyalgia patients...
  7. ncbi Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN 46221, USA
    Curr Med Res Opin 25:585-97. 2009
    ..To examine medical conditions associated with diabetic neuropathy (DN) and to identify drivers of healthcare charges and utilization using administrative claims...
  8. ncbi Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities
    Y Zhao
    Global Health Outcomes, Eli Lilly and Co, Indianapolis, IN 46221, USA
    Diabet Med 26:61-9. 2009
    ..The aim was to examine the impact of Type 1 diabetes and having any other diabetes-related complication or comorbidity on healthcare charges and utilization in patients with diabetic neuropathy (DN)...
  9. ncbi Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Health Serv Res 8:108. 2008
    ..This study uses a US administrative claims database to evaluate the effect of AD on direct healthcare costs and utilization, and to identify the most common reasons for AD patients' emergency room (ER) visits and inpatient admissions...
  10. ncbi Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia
    Peter Sun
    Kailo Research Group, Indianapolis, IN 46038, USA
    Curr Med Res Opin 27:1793-801. 2011
    ..To examine medication dosing patterns of duloxetine and pregabalin among patients with fibromyalgia...
  11. ncbi Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain
    Peter Sun
    Kailo Research Group, Fishers, IN 46038, USA
    Pain Pract 12:641-8. 2012
    ..To compare medication dosing patterns of duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain (DPNP)...
  12. ncbi Predictors of pain medication selection among patients diagnosed with fibromyalgia
    Luke Boulanger
    United BioSource Corporation, Lexington, Massachusetts, USA
    Pain Pract 12:266-75. 2012
    ..However, the factors associated with each treatment initiation have not been well established. This study assessed factors that were associated with the use of duloxetine vs. other pain medications among patients with fibromyalgia...
  13. ncbi Predicting pharmacy costs and other medical costs using diagnoses and drug claims
    Yang Zhao
    DxCG, Inc, Boston, Massachusetts, USA
    Med Care 43:34-43. 2005
    ..Predicting health care costs for individuals and populations is essential for managing care. However, the comparative power of diagnostic and drug data for predicting future costs has not been closely examined...
  14. ncbi Use of select medications prior to duloxetine initiation among commercially-insured patients
    Mark Bernauer
    Eli Lilly and Company, Indianapolis, IN
    J Pain Res 5:271-8. 2012
    ....
  15. ncbi Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine
    Zhanglin Cui
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 14:662-72. 2011
    ..To examine healthcare cost patterns prior to and following duloxetine initiation in patients with major depressive disorder (MDD), focusing on patients initiated at or titrated to high doses...
  16. ncbi Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
    Wenyu Ye
    Lilly USA, LLC, Indianapolis, Indiana, USA
    BMC Psychiatry 11:19. 2011
    ....
  17. ncbi Healthcare costs associated with osteoarthritis in US patients
    T Kim Le
    Eli Lilly and Company, Indianapolis, IN, USA
    Pain Pract 12:633-40. 2012
    ..This study was to compare pharmacologic treatments and costs for newly diagnosed and existing osteoarthritis patients to assess unmet medication treatment needs and economic burden...
  18. ncbi Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    J Pain Res 5:443-51. 2012
    ..The purpose of this study was to examine the main reasons for inpatient or outpatient visits after initiating duloxetine or pregabalin...
  19. ncbi Predictors of duloxetine adherence and persistence in patients with fibromyalgia
    Zhanglin Cui
    Eli Lilly and Company, Indianapolis, IN, USA
    J Pain Res 5:193-201. 2012
    ....
  20. ncbi Implications of comorbidity on costs for patients with Alzheimer disease
    Tzu Chun Kuo
    Research Division, DxCG, Inc, Boston, Massachusetts 02110, USA
    Med Care 46:839-46. 2008
    ....
  21. ncbi Disease burden profiles: an emerging tool for managing managed care
    Yang Zhao
    DxCG, Inc, Boston, MA 02111, USA
    Health Care Manag Sci 5:211-9. 2002
    ..We also examine and compare the predictive power of claims-based models within a diabetic cohort...
  22. ncbi Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment
    Louis S Matza
    Center for Health Outcomes Research at UBC, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814, USA
    Schizophr Bull 32:666-78. 2006
    ..When creating new functional outcomes measures for assessment of patients with schizophrenia, responsiveness to change in CIAS should be evaluated as part of the development and validation process...